PET/CT imaging of clear cell renal cell carcinoma with 124I labeled chimeric antibody

9Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Clear cell renal cell carcinoma (ccRCC) presents problems for urologists in diagnosis, treatment selection, intraoperative surgical margin analysis, and long term monitoring. In this paper we describe the development of a radiolabeled antibody specific to ccRCC (124I-cG250) and its potential to help urologists manage each of these problems. We believe 124I-cG250, in conjunction with perioperative Positron emission tomography/ computed tomography imaging and intraoperative handheld gamma probe use, has the potential to diagnose ccRCC, aid in determining a proper course of treatment (operative or otherwise), confirm complete resection of malignant tissue in real time, and monitor patients post-operatively. © 2009, SAGE Publications. All rights reserved.

Cite

CITATION STYLE

APA

Bahnson, E. E., Murrey, D. A., Mojzisik, C. M., Hall, N. C., Martinez-Suarez, H. J., Knopp, M. V., … Bahnson, R. R. (2009). PET/CT imaging of clear cell renal cell carcinoma with 124I labeled chimeric antibody. Therapeutic Advances in Urology, 1(2), 67–70. https://doi.org/10.1177/1756287209105264

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free